Skip to main content
Signal8

Bowden Christopher

SEC insider (Form 3/4/5 filer). CIK 0001608601. Director at Bicara Therapeutics Inc. (BCAX). 2 reported Form 4/5 transactions since Sep 2024; latest on Jun 9, 2026. Located in BOSTON, MA.

Companies Bowden Christopher has filed insider reports for

  • Bicara Therapeutics Inc. (BCAX): Director
Bowden Christopher profile photo

Bowden Christopher

CIK: 0001608601

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Bicara Therapeutics Inc. logo
BCAX

Bicara Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

  • Bicara Therapeutics Inc. logo
    BCAX

    Bicara Therapeutics Inc.

    Jun 9, 2026
    Award

    Stock Option (Right to Buy)

    Direct
    19.5K shares-
  • Bicara Therapeutics Inc. logo
    BCAX

    Bicara Therapeutics Inc.

    Jun 9, 2025
    Award

    Stock Option (Right to Buy)

    Direct
    23.7K shares-

1-2 of 2